Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III elecoglipron with or without dapagliflozin versus placebo in adults with type 2 diabetes mellitus
PACTR202609768716927Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of elecoglipron and dapagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
elecogliprondapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202609768716927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609768716927.